FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure

 
• By Alaric DeArment
  
FibroGen said 5 May that the Phase III study of roxadustat in MDS did not meet its primary endpoint • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D